| Patent Number |
Title Of Patent |
Date Issued |
| 7262213 |
Compounds and methods for the treatment of cancer |
August 28, 2007 |
| (-)-(2S,4S)-1-(2-Hydroxymethyl-1,3-dioxolan-4-yl)cytosine (also referred to as (-)-OddC) or its derivative and its use to treat cancer in animals, including humans. |
| 7025993 |
Herbal composition PHY906 and its use in chemotherapy |
April 11, 2006 |
| This invention provides herbal compositions useful for increasing the therapeutic index of drugs, including those used in the treatment of disease, especially viral infections and neoplasms of cancer. This invention provides methods useful for improving the quality of life of an indi |
| 6960568 |
Nucleosides and related processes, pharmaceutical compositions and methods |
November 1, 2005 |
| The invention provides novel nucleosides and related processes, pharmaceutical compositions, and methods. The novel nucleosides are useful in a wide variety of antiviral, antineoplastic, and antibacterial applications. Preferred embodiments of the instant invention include novel 2 ha |
| 6911460 |
Antiviral agents and methods of treating viral infections |
June 28, 2005 |
| The present invention relates to methods of treating viral or fungal infections using 3-aminopyridine-2-carboxyaldehyde thiosemicarbazone (3-AP) and 3-amino-4-methylpyridine-2-carboxaldehyde thiosemicarbazone (3-AMP) and its prodrug forms and to pharmaceutical compositions comprising |
| 6653318 |
5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and me |
November 25, 2003 |
| The present invention relates to pyrimidine nucleoside compounds and their use to treat viral infections of Varicella Zoster virus and Epstein Barr Virus, as well as cancers which are complications of Epstein Barr virus. |
| 6436948 |
Method for the treatment of psoriasis and genital warts |
August 20, 2002 |
| The present invention relates to the use of prodrug forms of (-)-(2S,4S)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl)cytosine to treat psoriasis, genital warts and other hyperproliferative keratinocyte diseases such as hyperkeratosis, ichthyosis, keratoderma or lichen planus. |
| 6420377 |
Covalent conjugates of topoisomerase I and topoisomerase II inhibitors |
July 16, 2002 |
| The present invention provides covalent conjugates of topoisomerase I and topoisomerase II inhibitors. Such compounds have a structure according to formula I:wherein: T.sub.I is a topoisomerase I inhibitor such as a camptothecin group; T.sub.II is a topoisomerase II inhibitor such as a |
| 6306899 |
Inhibition and treatment of Hepatitis B virus and Flavivirus by Helioxanthin and its analogs |
October 23, 2001 |
| This invention relates to anti-viral drugs such as Helioxanthin and its analogs. The present compounds may be used alone or in combination with other drugs for the treatment of Hepatitis B virus (HBV), Hepatitis C virus (HCV), Yellow Fever, Dengue Virus, Japanese Encephalitis, West Nile |
| 6274589 |
L-.beta.-dioxolane uridine analogs and their pharmaceutical compositions |
August 14, 2001 |
| The present invention relates to the discovery that certain .beta.-L-dioxolane nucleoside analogs which contain a uracil base, and preferably, a 5-halosubstituted uracil base, exhibit unexpectedly high activity against Epstein-Barr virus (EBV), Varciella-Zoster virus (VZV) and Herpes |
| 6207673 |
Covalent conjugates of topoisomerase I and topoisomerase II inhibitors |
March 27, 2001 |
| The present invention provides covalent conjugates of topoisomerase I and topoisomerase II inhibitors. Such compounds have a structure according to formula I:wherein:T.sub.I is a topoisomerase I inhibitor such as a camptothecin group;T.sub.II is a topoisomerase II inhibitor such as an amsacr |
| 6063787 |
Methods for the treatment of psoriasis and genital warts |
May 16, 2000 |
| The present invention relates to the use of (-)-(2S,4S)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosine to treat psoriasis, genital warts and other hyperproliferative keratinocyte diseases such as hyperkeratosis, ichthyosis, keratoderma or lichen planus. |
| 6022876 |
L-.beta.-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus in |
February 8, 2000 |
| The present invention relates to the discovery that certain .beta.-L-dioxolane nucleoside analogs which contain a uracil base, and preferably, a 5-halosubstituted uracil base, exhibit unexpectedly high activity against Epstein-Barr virus (EBV), Varciella-Zoster virus (VZV) and Herpes |
| 5869461 |
Reducing toxicity of L-nucleosides with D-nucleosides |
February 9, 1999 |
| The present invention relates to novel methods for reducing toxicity associated with the administration of conventional "D" nucleoside compounds, including anti-HIV nucleosides and related therapeutic agents. Therapeutic methods which rely on conventional "D" nucleosides exhibit unex |
| 5830881 |
L-2'3',dideoxy nucleoside analogs as anti-hepatitus B (HBV) agents |
November 3, 1998 |
| The present invention relates to the surprising discovery that certain dideoxynucleoside analogs which contain a dideoxy ribofuranosyl moiety having an L-configuration (as opposed to the naturally occurring D- configuration) exhibit unexpected activity against Hepatitis B virus (HBV) |
| 5827727 |
Method of resolution of 1,3-oxathiolane nucleoside enantiomers |
October 27, 1998 |
| A process for the resolution of a racemic mixture of nucleoside enantiomers that includes the step of exposing the racemic mixture to an enzyme that preferentially catalyzes a reaction in one of the enantiomers. The nucleoside enantiomer (-)-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1 |
| 5817667 |
Compounds and methods for the treatment of cancer |
October 6, 1998 |
| (-)-(2S,4S)-1-(2-Hydroxymethyl-1,3-dioxolan-4-yl)cytosine (also referred to as (-)-OddC) and its use to treat cancer in animals, including humans. |
| 5808040 |
L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides |
September 15, 1998 |
| A method for stabilizing an oligonucleotide by including a .beta.-L-2'-deoxy-2'-fluoro-arabinofuranosyl nucleoside at the 5'-terminus, the 3'-terminus, or in the interior of the oligonucleotide. The oligonucleotide can be used in the modulation of gene expression through a process wh |
| 5792773 |
L-.beta.-dioxolane uridine analog administration for treating Epstein-Barr virus infection |
August 11, 1998 |
| The present invention relates to the discovery that certain .beta.-L-dioxolane nucleoside analogs which contain a uracil base, and preferably, a 5-halosubstituted uracil base, exhibit unexpectedly high activity against Epstein-Barr virus (EBV). In particular, the compounds according |
| 5756478 |
Method for reducing toxicity of D-nucleoside analogs with L-nucleosides |
May 26, 1998 |
| The present invention relates to novel methods for reducing toxicity associated with the administration of conventional "D" nucleoside compounds, including anti-HIV nucleosides and related therapeutic agents. Therapeutic methods which rely on conventional "D" nucleosides exhibit unex |
| 5753789 |
Oligonucleotides containing L-nucleosides |
May 19, 1998 |
| Oligonucleotides that include a 2'-fluoro .beta.-L-arabinofuranosyl nucleoside at the 3'-terminus, the 5'-terminus or in the interior of the oligomer. A preferred nucleoside is 2'-fluoro-5-methyl-.beta.-L-arabinofuranosyluridine (also referred to as L-FMAU). This compound is a potent |
| 5728684 |
Determination of prodrugs metabolizable by the liver and therapeutic use thereof |
March 17, 1998 |
| A method of ascertaining if a prodrug is useful for treating a disease is disclosed. The prodrug is acceptable if it is metabolized in liver cells by aldehyde oxidase to produce an active drug or metabolite. Prodrugs are shown equally effective in treating diseases as the active drug its |
| 5646126 |
Sterol modified oligonucleotide duplexes having anticancer activity |
July 8, 1997 |
| Oligonucleotides having approximately 8 to 18 nucleotide units and a 3'-tail which includes asteroid structure attached to the 3'-end through the A ring of the steroid skeleton and which form substantially stable duplexes at physiological temperature, have selective cytotoxic activity |
| 5631239 |
L-2',3'-dideoxy nucleoside analogs as anti-Hepatitis B (HBV) agents |
May 20, 1997 |
| The present invention relates to the surprising discovery that certain dideoxynucleoside analogs which contain a dideoxy ribofuranosyl moiety having an L-configuration (as opposed to the naturally occurring D- configuration) exhibit unexpected activity against Hepatitis B virus (HBV) |
| 5627160 |
L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents |
May 6, 1997 |
| The present invention relates to the surprising discovery that certain dideoxynucleoside analogs which contain a dideoxy ribofuranosyl moiety having an L-configuration (as opposed to the naturally occurring D-configuration) exhibit unexpected activity against Hepatitis B virus (HBV). |
| 5612341 |
Brominated hexahydroxybiphenyl derivatives |
March 18, 1997 |
| Disclosed herein are derivatives of 4,4'-dimethoxy-5,6,5'6'-bimethylenedioxy 2,2'-dimethoxycarbonyl biphenyl (DDB) which were synthesized and found to have anti-HIV activity. Of the compounds studied, 3,3'-dibromo DDB and 3-bromo-DDB initially exhibited the greatest anti-HIV activity |
| 5587362 |
L-nucleosides |
December 24, 1996 |
| A compound, and a pharmaceutical composition comprising an effective mount to treat HBV or EBV of a compound, of the formula: ##STR1## wherein R is selected from the group consisting of 5-methyluracil, adenine and cytosine, and R' is hydrogen, acyl, or alkyl or a monophosphate, d |
| 5567688 |
L-nucleosides for the treatment of hepatitis B-virus |
October 22, 1996 |
| A method for the treatment of a human infected with HBV that includes administering an HBV-treatment amount of an L-nucleoside of the formula: ##STR1## wherein R is selected from the group consisting of 5-methyluracil, adenine and cytosine, and R' is hydrogen, acyl, alkyl or a monoph |
| 5565438 |
L-nucleosides for the treatment of epstein-bar virus |
October 15, 1996 |
| A method for the treatment of a human infected with EBV that includes administering an EBV-treatment amount of an L-nucleoside of the formula: ##STR1## wherein R is 5-methyluracil, and R' is hydrogen, acyl, alkyl or a monophosphate, diphosphate or triphosphate ester, or its pharmaceu |
| 5561120 |
Method for treating HBV infections with L-2',3'-didehydro-dideoxy-5-fluorocytidine |
October 1, 1996 |
| The present invention relates to the surprising discovery that certain dideoxynucleoside analogs which contain a dideoxy ribofuranosyl moiety having an L-configuration (as opposed to the naturally occurring D- configuration) exhibit unexpected activity against Hepatitis B virus (HBV) |
| 5541223 |
4.beta.-amino podophyllotoxin analog compounds and methods |
July 30, 1996 |
| Novel podophyllotoxin compounds and their use in treating tumors are disclosed. The analogs have the general formula: ##STR1## wherein NH--R is a selected aryl amine, dialkylaminoalkyleneamino, or dialkylaminoanilino group. |
| 5332811 |
Etopside analogs |
July 26, 1994 |
| Compounds which are analogs of etoposide and which exhibit anti-tumor activity are disclosed. These compounds having the following structure: ##STR1## wherein R is selected from ##STR2## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are each independently selected fr |
| 5300500 |
4 beta-amino podophyllotoxin analog compounds and methods |
April 5, 1994 |
| Novel podophyllotoxin compounds and their use in treating tumors are disclosed. In one embodiment, the compounds have the general formula: ##STR1## wherein NH-R is a selected from the from the group consisting of: ##STR2## |
| 5192764 |
Pyrazinone N-oxide nucleosides and analogs thereof |
March 9, 1993 |
| This invention relates to nucleoside and acyclo analogs containing 5- or 6-substituted 2-pyrazinone-4-N-oxide. These compounds are useful for treating various conditions including viral infections, cancer, fungal infections, bacterial infections, microbial infections and related disease |
| 5132322 |
Etoposide analogues |
July 21, 1992 |
| Compounds that are analogs of etoposide and exhibit antitumor activity are disclosed. The compounds of the present invention have the following formula: ##STR1## where: R.sub.1 is .beta.-OCH.sub.2 CH.sub.2 NH.sub.2 .beta.-NHCH(CH.sub.3)CH.sub.2 OH, .beta.-NHCH.sub.2 CH(CH.sub.3)O |
| 5008252 |
Process for inhibiting herpes simplex virus-specified thymidine kinase |
April 16, 1991 |
| The invention relates to a method of selectively inhibiting herpes simplex virus-specified thymidine kinase. The method comprises exposing mammalian cells infected with the virus to an effective amount of 5'-ethynylthymidine. The invention further relates to a pharmaceutical composit |
| 4895937 |
5-ioso-2-pyrimidinone nucleoside |
January 23, 1990 |
| The nuceoside 1-(2-Deoxy-.beta.-D-ribofuranosyl)-5-(iodo)-2-pyrimidinone possesses a high level of antiviral activity and a low level of toxicity to the host cell making it an especially effective therapeutic agent for HSV-2. |
| 4782142 |
Novel 5-substituted 2-pyrimidinone nucleosides and methods of use |
November 1, 1988 |
| Compounds for inhibiting the replication of DNA viruses which induce the formation of thymidine kinase enzyme of the formula: ##STR1## wherein R.sub.1 is a radical selected from the group consisting of chloro, iodo, hydroxy, alkoxyalkyl, hydroxyalkyl, methylamino, formyl, nitro, and |
| 4468384 |
Method for the inhibition of the replication of DNA viruses with 5-substituted 2-pyrimidinone nu |
August 28, 1984 |
| A method for inhibiting the replication of a DNA virus which induces formation of thymidine kinase enzyme, by exposing the virus to an effective concentration of a compound of the formula: ##STR1## wherein R.sub.1 is a radical selected from the group consisting of halogen, --SCH. |
| 4321366 |
Process of preparing 2-azido-2-deoxyarabinofuranosyl halides |
March 23, 1982 |
| Novel arabinofuranosyl nucleosides and nucleotides having 2'-azido,2'-amino, or 2'-hydrocarbylamino substituents, which have antitumor, antiviral, and antimicrobial properties, are prepared by condensation of a pyrimidine, purine, or 1,3-oxazine base with an acylated 2-azido-2-deoxya |
| 4230698 |
2-Substituted arabinofuranosyl nucleosides and nucleotides |
October 28, 1980 |
| Novel arabinofuranosyl nucleosides and nucleotides having 2'-azido, 2'-amino, or 2'-hydrocarbylamino substituents, which have antitumor, antiviral, and antimicrobial properties, are prepared by condensation of a pyrimidine, purine, or 1,3-oxazine base with an acylated 2-azido-2-deoxy |
| 4000260 |
Anti herpes simplex viral compounds and their synthesis |
December 28, 1976 |
| The compounds 5'-amino-2',5'-dideoxy-5-iodouridine; 5'-amino-2',5'-dideoxy-5-bromouridine; and the pharmaceutically acceptable acid addition salts thereof have been found to be potent inhibitors of herpes simplex virus. |
